

Customer-Focused Product Flow

| | | Key Products | Market Facts / 2001 Milestones |
|--|---|--|--|
| Prescription Pharmaceuticals | Primary Care | Celebrex (celecoxib capsules) | <ul style="list-style-type: none"> • 2001 Sales: \$3.1 billion (+19%) • Number one selling prescription arthritis brand worldwide • Approved for new indications in pain and dysmenorrhea by U.S. FDA • Clinical studies in lung cancer prevention initiated by National Cancer Institute and UCLA |
| | | Bextra (valdecoxib tablets) | <ul style="list-style-type: none"> • First second-generation oral COX-2 specific inhibitor approved by U.S. FDA |
| | | Detrol/Detrol LA (tolterodine tartrate tablets) | <ul style="list-style-type: none"> • 2001 Sales: \$617 million (+43%) • Leading global overactive bladder therapy • Once-daily sustained release formulation launched in U.S. and Europe |
| | | Mirapex (pramipexole tablets) Cabaser (cabergoline tablets) | <ul style="list-style-type: none"> • 2001 Sales: Mirapex, \$148 million (+30%); Cabaser, \$165 million (+33%) • Leading dopamine agonist therapies for Parkinson's disease symptoms |
| | Ophthalmology | Xalatan (latanoprost ophthalmologic solution) | <ul style="list-style-type: none"> • 2001 Sales: \$818 million (+18%) • World's top-selling glaucoma medication • Becomes number one selling glaucoma treatment in Japan • Combination therapy Xalacom (Xalatan + timolol) launched in Europe |
| | Hospital Care | Zyvox (linezolid injection, tablets, and for oral suspension) | <ul style="list-style-type: none"> • 2001 Sales: \$108 million (+125%) • First new class of antibiotics launched in more than 30 years • Approved in U.S., Europe and Japan within 12 months |
| | | Medrol (methylprednisolone tablets, IV and injection) | <ul style="list-style-type: none"> • 2001 Sales: \$323 million (+14%) • Global leader in injectable corticosteroid market |
| | | Dynastat (parecoxib solution for injection) | <ul style="list-style-type: none"> • First second-generation injectable COX-2 specific inhibitor approved in Europe |
| | | Fragmin (dalteparin sodium injection) | <ul style="list-style-type: none"> • 2001 Sales: \$226 million (+7%) • U.S. sales increased 60 percent to \$59 million |
| | Cancer Care | Camptosar (irinotecan hydrochloride injection) | <ul style="list-style-type: none"> • 2001 Sales: \$613 million (+39%) • New standard in the treatment of metastatic colorectal cancer • Survival benefit of first-line regimen confirmed by FDA Oncologic Drugs Advisory Committee • Phase III studies initiated in pancreatic, small cell lung and early-stage colorectal cancers |
| Ellence/Pharmorubicin (epirubicin hydrochloride injection) | | <ul style="list-style-type: none"> • 2001 Sales: \$261 million (+31%) • Market-leading anthracycline therapy | |
| Aromasin (exemestane tablets) | | <ul style="list-style-type: none"> • 2001 Sales: \$47 million (+102%) • New studies show potential benefit in early-stage breast cancer | |
| Endocrine Care | Genotropin (somatropin [rDNA origin] for injection) | <ul style="list-style-type: none"> • 2001 Sales: \$511 million (+9%) • World's leading recombinant growth hormone • Approved in U.S. for use in children born small for gestational age (SGA) | |
| | Somavert (pegvisomant) | <ul style="list-style-type: none"> • Granted approvable letter in U.S. for acromegaly (gigantism) • Pivotal efficacy study published in New England Journal of Medicine | |
| Consumer Healthcare | | Nicorette/Nicotrol | <ul style="list-style-type: none"> • 2001 Sales: \$299 million (+37%) • Launched first OTC smoking cessation product in Japan • Reacquired sales and marketing rights to Nicorette gum in Canada |